Search results for "Hypertriglyceridemia"

showing 10 items of 82 documents

Serum Amino Acid Profiles in Childhood Predict Triglyceride Level in Adulthood: A 7-Year Longitudinal Study in Girls.

2016

AbstractContext:Branched-chain and aromatic amino acids are associated with high risk of developing dyslipidemia and type II diabetes in adults.Objective:This study aimed to examine whether serum amino acid profiles associate with triglyceride concentrations during pubertal growth and predict hypertriglyceridemia in early adulthood.Design:This was a 7.5-year longitudinal study.Setting:The study was conducted at the Health Science Laboratory, University of Jyväskylä.Participants:A total of 396 nondiabetic Finnish girls aged 11.2 ± 0.8 years at the baseline participated in the study.Main Outcome Measures:Body composition was assessed by dual-energy x-ray absorptiometry; serum concentrations o…

0301 basic medicineBlood GlucoseLongitudinal studymedicine.medical_specialtyMagnetic Resonance SpectroscopyAdolescentEndocrinology Diabetes and Metabolismmedicine.medical_treatmentClinical BiochemistryContext (language use)030204 cardiovascular system & hematologyBiochemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyAbsorptiometry PhotonInternal medicinemedicineHumansInsulinLongitudinal StudiesAmino AcidsChildTriglyceridesTriglyceridebusiness.industryInsulinBiochemistry (medical)Hypertriglyceridemiamedicine.disease030104 developmental biologyEndocrinologychemistryBody CompositionFemaleIsoleucineLeucinebusinessDyslipidemiaThe Journal of clinical endocrinology and metabolism
researchProduct

Deregulated Lipid Sensing by Intestinal CD36 in Diet-Induced Hyperinsulinemic Obese Mouse Model

2016

International audience; The metabolic syndrome (MetS) greatly increases risk of cardiovascular disease and diabetes and is generally associated with abnormally elevated postprandial triglyceride levels. We evaluated intestinal synthesis of triglyceride-rich lipoproteins (TRL) in a mouse model of the MetS obtained by feeding a palm oil-rich high fat diet (HFD). By contrast to control mice, MetS mice secreted two populations of TRL. If the smaller size population represented 44% of total particles in the beginning of intestinal lipid absorption in MetS mice, it accounted for only 17% after 4 h due to the secretion of larger size TRL. The MetS mice displayed accentuated postprandial hypertrigl…

0301 basic medicineCD36 Antigens[SDV]Life Sciences [q-bio]lcsh:Medicine030204 cardiovascular system & hematologyLipoprotein MetabolismMice0302 clinical medicineIntestinal mucosaHyperinsulinemiaIntestinal Mucosalcsh:ScienceMetabolic Syndromeeducation.field_of_studyMultidisciplinaryIntestinal lipid absorption3. Good healthPostprandialChain Fatty-Acidslipids (amino acids peptides and proteins)Research ArticleNonfasting Triglyceridesmedicine.medical_specialtyPopulationTransportDistal IntestineBiologyDiet High-FatAbsorption03 medical and health sciencesInsulin resistanceInternal medicineHyperinsulinismmedicineAnimalsCholesterol UptakeObesityeducationSecretion[ SDV ] Life Sciences [q-bio]Insulin-Resistancelcsh:RHypertriglyceridemiaLipid metabolismmedicine.diseaseLipid MetabolismDisease Models Animal030104 developmental biologyEndocrinologyGene Expression Regulationlcsh:Q[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition
researchProduct

Pistachio Consumption Prevents and Improves Lipid Dysmetabolism by Reducing the Lipid Metabolizing Gene Expression in Diet-Induced Obese Mice.

2018

Pistachios contain beneficial substances such as unsaturated fatty acids, phytosterols, and polyphenols. In the present study, we investigated if pistachio consumption is able to prevent or to revert hyperglycemia, dyslipidemia, hepatic steatosis, and adipose tissue morphological alterations caused by high fat diet (HFD) in the mouse. Moreover, the impact of pistachio intake on the mRNA expression of peroxisome proliferator-activated receptor &gamma

0301 basic medicineMaleAdipose tissueMice ObeseSettore BIO/09 - Fisiologiachemistry.chemical_compoundAdipocytelipid metabolizing gene expressionNutsHypertriglyceridemiaNutrition and Dieteticsbiologyfood and beveragesPhytosterolsFatty acid synthaseCholesterolAdipose TissueLiverPistacialipids (amino acids peptides and proteins)Sterol Regulatory Element Binding Protein 1lcsh:Nutrition. Foods and food supplyStearoyl-CoA Desaturasemedicine.medical_specialtyobesity-related dysfunctionslcsh:TX341-641pistachio consumptionDiet High-FatArticle03 medical and health sciencesInternal medicineobesity-related dysfunctionmedicineAnimalsObesityRNA MessengerDyslipidemias030109 nutrition & dieteticsFatty Acid Transport ProteinsPlant ExtractsHypertriglyceridemianutritional and metabolic diseasesPolyphenolsLipid metabolismmedicine.diseaseLipid MetabolismDietFatty LiverMice Inbred C57BLPPAR gammaEndocrinologychemistrybiology.proteinSteatosisFatty Acid SynthasesDiet-induced obeseFood ScienceNutrients
researchProduct

Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohor…

2019

Abstract Background Study aim was to evaluate the safety and durability of darunavir/cobicistat (DRV/c) in a real life setting. Methods Multicentre prospective cohort study performed in the context of SCOLTA (Surveillance Cohort Long-Term Toxicity Antiretrovirals). Patients were evaluated at baseline, week 24 and 48. Changes were evaluated using the paired t test or signed rank test. The multivariable analysis was performed using a general linear model, after ranking of not normally distributed variables. Results A total of 249 patients were included, 72 (29%) were in DRV/c-based dual therapies (DT). Hypercholesterolemia, HC, (total cholesterol (TC) ≥ 200 mg/dL or low density-C (LDL-C) ≥ 13…

0301 basic medicineMaleHIV Infections0302 clinical medicineDualMedicineHIV InfectionPharmacology (medical)030212 general & internal medicineProspective StudiesProspective cohort studyDarunavirCobicistatMiddle AgedViral LoadTolerabilityTolerabilityAnti-Retroviral AgentsCohortMolecular MedicineDrug Therapy CombinationFemaleDarunavir/cobicistatHumanmedicine.drugAdverse eventAdultlcsh:Immunologic diseases. Allergymedicine.medical_specialty030106 microbiologyContext (language use)Durability03 medical and health sciencesDarunavir/cobicistat Dual Durability Tolerability CISAI Adverse eventsVirologyInternal medicineHumansDarunavirbusiness.industryResearchHypertriglyceridemiamedicine.diseaseCISAIDiscontinuationProspective StudieAdverse eventsHIV-1Anti-Retroviral AgentCobicistatbusinesslcsh:RC581-607
researchProduct

Dietary protein restriction reduces circulating VLDL triglyceride levels via CREBH-APOA5-dependent and -independent mechanisms

2018

Hypertriglyceridemia is an independent risk factor for cardiovascular disease. Dietary interventions based on protein restriction (PR) reduce circulating triglycerides (TGs), but underlying mechanisms and clinical relevance remain unclear. Here, we show that 1 week of a protein-free diet without enforced calorie restriction significantly lowered circulating TGs in both lean and diet-induced obese mice. Mechanistically, the TG-lowering effect of PR was due, in part, to changes in very low-density lipoprotein (VLDL) metabolism both in liver and peripheral tissues. In the periphery, PR stimulated VLDL-TG consumption by increasing VLDL-bound APOA5 expression and promoting VLDL-TG hydrolysis and…

0301 basic medicineMalemedicine.medical_specialtyVery low-density lipoproteinDietary proteinFGF21Calorie restrictionmTORC1Lipoproteins VLDLMechanistic Target of Rapamycin Complex 1Protein Serine-Threonine Kinases03 medical and health sciencesMice0302 clinical medicineRisk FactorsInternal medicinemedicineDiet Protein-RestrictedIntegrated stress responseAnimalsHumansCyclic AMP Response Element-Binding ProteinTriglyceridesRandomized Controlled Trials as TopicHypertriglyceridemiaChemistryHydrolysisHypertriglyceridemianutritional and metabolic diseasesGeneral Medicinemedicine.diseaseLipid Metabolism030104 developmental biologyEndocrinologyApolipoproteinsHypotriglyceridemiaLiverApolipoprotein A-Vlipids (amino acids peptides and proteins)Female030217 neurology & neurosurgeryLipoproteinResearch Article
researchProduct

The role of registries in rare genetic lipid disorders: Review and introduction of the first global registry in lipoprotein lipase deficiency

2017

International audience; A good understanding of the natural history of rare genetic lipid disorders is a pre-requisite for successful patient management. Disease registries have been helpful in this regard. Lipoprotein Lipase Deficiency (LPLD) is a rare, autosomal-recessive lipid disorder characterized by severe hypertriglyceridemia and a very high risk for recurrent acute pancreatitis, however, only limited data are available on its natural course. Alipogene tiparvovec (Glybera (R)) is the first gene therapy to receive Marketing Authorization in the European Union; GENIALL (GENetherapy In the MAnagement of Lipoprotein Lipase Deficiency), a 15-year registry focusing on LPLD was launched in …

0301 basic medicinePediatricsPathologySettore MED/09 - Medicina Interna[SDV]Life Sciences [q-bio]Familial hypercholesterolemiaDisease030204 cardiovascular system & hematologyGeneTHERAPY0302 clinical medicineFamilialRisk FactorsHyperchylomicronemiaAlipogene tiparvovecRegistriesFAMILIAL HYPERCHOLESTEROLEMIAmedia_commonHypertriglyceridemiaPrognosis3. Good healthNatural historySystematic reviewPhenotypeDISEASESSAFETYHyperlipoproteinemia Type ICardiology and Cardiovascular Medicinemedicine.medical_specialtyAPHERESISRegistryFamilial chylomicronemia syndromeGENIALLLysosomal acid lipase deficiencyLipid Metabolism Inborn Errors03 medical and health sciencesLipoprotein lipase deficiencyRare DiseasesGene therapychylomicronemia syndromemedicinemedia_common.cataloged_instanceHumansGenetic Predisposition to DiseaseEuropean unionLipoprotein lipase deficiency (LPLD)business.industryALIPOGENE TIPARVOVEC AAV1-LPLS447Xmedicine.diseaseAlipogene tiparvovecLipoprotein Lipase030104 developmental biologyOrphan diseasebusiness
researchProduct

Expert opinion on the metabolic complications of mTOR inhibitors

2018

Abstract Using mTOR inhibitors (mTORi) as anticancer drugs led to hyperglycemia (12–50%) and hyperlipidemia (7–73%) in phase-III trials. These high rates require adapted treatment in cancer patients. Before initiating mTORi treatment, lipid profile screening should be systematic, with fasting glucose assay in non-diabetic patients and HbA1C in diabetic patients. After initiation, lipid profile monitoring should be systematic, with fasting glucose assay in non-diabetic patients, every 2 weeks for the first month and then monthly. The HbA1C target is ≤ 8%, before and after treatment initiation in known diabetic patients and in case of onset of diabetes under mTORi. LDL-cholesterol targets sho…

0301 basic medicinemedicine.medical_specialtyConsensusEndocrinology Diabetes and MetabolismAtorvastatinAntineoplastic Agents03 medical and health sciences0302 clinical medicineEndocrinologyMetabolic DiseasesNeoplasmsInternal medicineDiabetes mellitusHyperlipidemiamedicineHumansDyslipidemiasFenofibratemedicine.diagnostic_testbusiness.industryTOR Serine-Threonine KinasesHypertriglyceridemianutritional and metabolic diseasesGeneral Medicinemedicine.diseaseHypoglycemia030104 developmental biologySimvastatin030220 oncology & carcinogenesislipids (amino acids peptides and proteins)Lipid profilebusinessPravastatinmedicine.drugAnnales d'Endocrinologie
researchProduct

PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients

2019

Dyslipidemia and altered iron metabolism are typical features of nonalcoholic fatty liver disease (NAFLD). Proprotein convertase subtilisin/kexin type 7 (PCSK7) gene variation has been associated with circulating lipids and liver damage during iron overload. The aim of this study was to examine the impact of the PCSK7 rs236918 variant on NAFLDrelated traits in 1,801 individuals from the Liver Biopsy Cohort (LBC), 500,000 from the UK Biobank Cohort (UKBBC), and 4,580 from the Dallas Heart Study (DHS). The minor PCSK7 rs236918 C allele was associated with higher triglycerides, aminotransferases, and hepatic inflammation in the LBC (P < 0.05) and with hypercholesterolemia and liver disease …

0301 basic medicinenonalcoholic fatty liver diseasemedicine.medical_specialtyDyslipidemias; Genetics; Inflammation; Liver; Triglycerides; genes in lipid dysfunction; metabolic disease; non-alcoholic fatty liver diseaseHyperlipidemiasInflammationQD415-436030204 cardiovascular system & hematologyBiochemistryproprotein convertase subtilisin/kexin type 703 medical and health sciencesLiver disease0302 clinical medicineEndocrinologyGeneticInternal medicineNonalcoholic fatty liver diseasemedicineGeneticsHumansSubtilisinsAlleleTriglyceridesDyslipidemiasHypertriglyceridemiaInflammationgenes in lipid dysfunctionmedicine.diagnostic_testbusiness.industrynon-alcoholic fatty liver diseaseCell Biologymedicine.diseasemetabolic disease030104 developmental biologyEndocrinologyLiverLiver biopsyLipogenesisKexinmedicine.symptomPatient-Oriented and Epidemiological ResearchbusinessDyslipidemia
researchProduct

Effectiveness and safety of lomitapide in a patient with familial chylomicronemia syndrome

2020

Background: Familial chylomicronemia syndrome (FCS) is characterized by severe fasting hypertriglyceridemia, abdominal pain, and recurrent acute pancreatitis. Available triglyceride-lowering drugs are insufficient to avoid pancreatitis. Therefore, there is a significant unmet medical need for effective triglyceride-lowering drugs for patients with FCS. Case report: We report the second case of a patient with FCS and recurrent pancreatitis treated with lomitapide. Lomitapide treatment resulted in a reduction of fasting TG levels from 2897 mg/dL (32.71 mmol/L) to an average of 954 mg/dL (10.77 mmol/L) on the 30 mg lomitapide equating to a 67% reduction from baseline. After 26 months of lomita…

Abdominal painPediatricsmedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismGastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyRecurrent pancreatitisInternal medicineFatty liverHumansMedicineProspective Studiesmedicine.diagnostic_testbusiness.industryFatty liverHypertriglyceridemiaFCSFamilial Chylomicronemiamedicine.diseaseLomitapideLomitapideAcute pancreatitisPancreatitischemistry030220 oncology & carcinogenesisLiver biopsyAcute DiseaseAcute pancreatitisPancreatitisBenzimidazolesHyperlipoproteinemia Type Ilipids (amino acids peptides and proteins)medicine.symptomCardiology and Cardiovascular MedicinebusinessFamilial chylomicronaemia syndromeAtherosclerosis
researchProduct

Plasma viscosity and related cardiovascular risk factors in a Spanish Mediterranean population

2006

Plasma viscosity (PV) constitutes an independent important predictor of initial and recurrent cardiac events and mortality. It has been suggested that there is a geographical variation in PV values related to coronary event rates. Little information exists regarding PV in Spain. Therefore, our objective was to determine PV in a large sample of randomly selected subjects from the Spanish population and to study which demographic or cardiovascular risk factors (CVRF) influence levels of PV in this population.1277 subjects (503 males, 774 females) aged 43+/-14 years (range: 20-70) were randomly selected from an Eastern Spanish population. These subjects were free of cardiovascular diseases and…

AdultBlood GlucoseMalemedicine.medical_specialtyMultivariate analysisPopulationPopulation GroupsRisk FactorsDiabetes mellitusInternal medicinemedicineHumansmedia_common.cataloged_instanceEuropean unionRisk factoreducationTriglyceridesAgedmedia_commoneducation.field_of_studyMediterranean Regionbusiness.industryHypertriglyceridemiaFibrinogenHematologyMiddle AgedBlood Viscositymedicine.diseaseObesityCholesterolEndocrinologyCardiovascular DiseasesSpainFemalebusinessBody mass indexBiomarkersDemographyThrombosis Research
researchProduct